Why Did Diagnos (TSXV:ADK) Expand Its U.S. Advisory Board On TSX Venture Composite Index?

Highlights:

• Diagnos announced the addition of an optometry expert to its U.S. advisory board.

• The company operates in the healthcare sector, providing artificial intelligence-based retinal screening solutions.

• The advisory board’s expansion supports Diagnos' medical technology focus across healthcare networks.

Diagnos (TSXV:ADK), a participant in the healthcare sector, is listed on the TSX Venture Composite Index (JX). The company specializes in artificial intelligence-based medical technologies, providing early detection services for retinal diseases. Diagnos collaborates with healthcare providers, clinics, and hospitals to deliver advanced screening platforms that assist in identifying eye-related conditions at earlier stages.

Diagnos focuses on offering solutions that integrate artificial intelligence with medical imaging, specifically targeting diabetic retinopathy and other retinal disorders. The company’s technology aims to support healthcare systems by enhancing diagnostic efficiency within clinical workflows.

Advisory Board Expansion Announcement

Diagnos announced the expansion of its U.S. advisory board with the appointment of Dr. Barry Ginsberg, an experienced figure in the field of optometry. Dr. Ginsberg joins the advisory board to support the company’s activities focused on advancing its artificial intelligence-driven healthcare solutions.

The U.S. advisory board plays a significant role in providing strategic input for Diagnos’ clinical programs and diagnostic offerings. The addition of a specialist in optometry brings medical expertise that is aligned with the company’s core focus on eye health and early detection services.

Professional Background of Dr. Barry Ginsberg

Dr. Barry Ginsberg brings experience in clinical eye care, diabetic eye health, and retinal examinations. His professional background covers years of direct involvement in optometric practice, patient care, and diagnostic processes.

Dr. Ginsberg has contributed to the development of screening practices aimed at enhancing early identification of retinal diseases. His experience with diabetic retinopathy detection aligns with Diagnos' objective to provide accessible and efficient screening solutions that support both healthcare providers and patients.

Role of the U.S. Advisory Board in Diagnos’ Strategy

The U.S. advisory board supports Diagnos by offering guidance on the clinical and operational aspects of its artificial intelligence platforms. Board members bring medical knowledge from a variety of healthcare fields, contributing to the company’s technology deployment strategies.

The advisory board works closely with healthcare professionals, technology teams, and industry partners to strengthen Diagnos’ screening capabilities. It provides recommendations for clinical adoption, system integration, and improved access to screening services across healthcare settings.

The inclusion of Dr. Ginsberg enhances the board’s ability to evaluate diagnostic practices from an optometric perspective. This input is valuable in refining the company’s screening programs to better align with clinical needs and improve service delivery.

Diagnos’ Focus on Artificial Intelligence and Screening Technologies

Diagnos offers artificial intelligence-based platforms that are designed to improve early detection in retinal health assessments. The company’s technologies process retinal images to assist healthcare professionals in identifying signs of diabetic retinopathy and other eye conditions at earlier stages.

The company’s screening solutions integrate artificial intelligence algorithms with advanced imaging tools, enabling clinics to efficiently conduct eye health assessments. These solutions are tailored to provide consistent and accurate results, supporting healthcare systems in addressing retinal diseases.

The U.S. advisory board, supported by the recent appointment, continues to play an active role in shaping the clinical direction of Diagnos’ artificial intelligence services. The collaboration between medical experts and technology developers remains central to the company’s approach in delivering screening solutions to the healthcare market.